- Home
- SFHG vs BLRX Comparison
SFHG vs BLRX Comparison
Compare SFHG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFHG
- BLRX
- Stock Information
- Founded
- SFHG 1993
- BLRX 2003
- Country
- SFHG Hong Kong
- BLRX Israel
- Employees
- SFHG N/A
- BLRX N/A
- Industry
- SFHG Publishing
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SFHG Consumer Discretionary
- BLRX Health Care
- Exchange
- SFHG Nasdaq
- BLRX Nasdaq
- Market Cap
- SFHG 16.2M
- BLRX 15.3M
- IPO Year
- SFHG 2024
- BLRX 2011
- Fundamental
- Price
- SFHG $0.78
- BLRX $4.49
- Analyst Decision
- SFHG
- BLRX Strong Buy
- Analyst Count
- SFHG 0
- BLRX 2
- Target Price
- SFHG N/A
- BLRX $19.00
- AVG Volume (30 Days)
- SFHG 49.7K
- BLRX 190.6K
- Earning Date
- SFHG 07-15-2025
- BLRX 08-14-2025
- Dividend Yield
- SFHG N/A
- BLRX N/A
- EPS Growth
- SFHG N/A
- BLRX N/A
- EPS
- SFHG N/A
- BLRX N/A
- Revenue
- SFHG $19,760,935.00
- BLRX $22,340,000.00
- Revenue This Year
- SFHG N/A
- BLRX N/A
- Revenue Next Year
- SFHG N/A
- BLRX N/A
- P/E Ratio
- SFHG N/A
- BLRX N/A
- Revenue Growth
- SFHG 30.89
- BLRX 91.68
- 52 Week Low
- SFHG $0.55
- BLRX $2.30
- 52 Week High
- SFHG $24.00
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- SFHG N/A
- BLRX 51.09
- Support Level
- SFHG N/A
- BLRX $4.35
- Resistance Level
- SFHG N/A
- BLRX $4.64
- Average True Range (ATR)
- SFHG 0.00
- BLRX 0.40
- MACD
- SFHG 0.00
- BLRX -0.07
- Stochastic Oscillator
- SFHG 0.00
- BLRX 47.30
About SFHG Samfine Creation Holdings Group Limited Ordinary Share
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.